Carregant...
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3...
Guardat en:
| Publicat a: | ESMO Open |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5070246/ https://ncbi.nlm.nih.gov/pubmed/27843627 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000073 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|